Liraglutide Liraglutide (Victoza/Saxenda) was the first GLP-1 agonist studied in PCOS populations with methodological rigor
The Breakthrough T1D-funded ADJUST-T1D trial demonstrated glycemic and metabolic benefits for people with T1D and obesity or overweight using an AID system treated with semaglutide
DSIP effects are more immediate and shorter-lasting, typically diminishing within days to a week after discontinuation
Still, some people may experience mild irritation, redness, and general sensitivity to active ingredients on the skin and scalp, especially when first introducing them into your routine
Even for people who are more primarily focused on performance enhancement, be it mental or physical, a unique, individualized peptide selection could potentially move the needle better than anything, they've tried before